Retevmo TM
Listen to the Pronunciation:
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: selpercatinib
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Blue opaque capsule imprinted with Lilly 2980 and 80 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 112 pack
- 14 pack
- 28 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Blue opaque capsule imprinted with Lilly 2980 and 80 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 112 pack
- 14 pack
- 28 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Blue opaque capsule imprinted with Lilly 2980 and 80 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 112 pack
- 14 pack
- 28 pack
- 56 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Blue opaque capsule imprinted with Lilly 2980 and 80 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 112 pack
- 14 pack
- 28 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 40 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Grey opaque capsule imprinted with Lilly 3977 and 40 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 14 pack
- 168 pack
- 42 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 40 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Grey opaque capsule imprinted with Lilly 3977 and 40 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 14 pack
- 168 pack
- 42 pack
- 56 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 40 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Grey opaque capsule imprinted with Lilly 3977 and 40 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 14 pack
- 168 pack
- 42 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 40 mg immediate release capsulesConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Grey opaque capsule imprinted with Lilly 3977 and 40 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 14 pack
- 168 pack
- 42 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 120 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- light purple, round tablet debossed with Ret 120 on one side and 6120 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 120 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- light purple, round tablet debossed with Ret 120 on one side and 6120 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 160 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- light pink, round tablet debossed with Ret 160 on one side and 5562 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 160 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- light pink, round tablet debossed with Ret 160 on one side and 5562 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 40 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- light grey, round tablet debossed with Ret 40 on one side and 5340 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 40 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- light grey, round tablet debossed with Ret 40 on one side and 5340 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- dark red-purple, round tablet debossed with Ret 80 on one side and 6082 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg film-coated tablets blister packWhat this medicine is used for
(ARTG)
RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,RETEVMO is indicated for the treatment of adult and adolescent (12 years of age and older) patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- dark red-purple, round tablet debossed with Ret 80 on one side and 6082 on the other
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 28 tablets pack
- 56 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
